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Abstract
Background: Lymphangiogenesis is a highly regulated process involved in the pathogenesis of disease. Current in vivo
models to assess lymphangiogenesis are largely unphysiologic. The zebrafish is a powerful model system for studying
development, due to its rapid growth and transparency during early stages of life. Identification of a network of trunk
lymphatic capillaries in zebrafish provides an opportunity to quantify lymphatic growth in vivo.
Methods and Results: Late-phase microangiography was used to detect trunk lymphatic capillaries in zebrafish 2- and 3-
days post-fertilization. Using this approach, real-time changes in lymphatic capillary development were measured in
response to modulators of lymphangiogenesis. Recombinant human vascular endothelial growth factor (VEGF)-C added
directly to the zebrafish aqueous environment as well as human endothelial and mouse melanoma cell transplantation
resulted in increased lymphatic capillary growth, while morpholino-based knockdown of vegfc and chemical inhibitors of
lymphangiogenesis added to the aqueous environment resulted in decreased lymphatic capillary growth.
Conclusion: Lymphatic capillaries in embryonic and larval zebrafish can be quantified using late-phase microangiography.
Human activators and small molecule inhibitors of lymphangiogenesis, as well as transplanted human endothelial and
mouse melanoma cells, alter lymphatic capillary development in zebrafish. The ability to rapidly quantify changes in
lymphatic growth under physiologic conditions will allow for broad screening of lymphangiogenesis modulators, as well as
help define cellular roles and elucidate pathways of lymphatic development.
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Introduction
Lymphangiogenesis, the formation of new lymphatic vessels, is
a highly regulated process and an important therapeutic drug
target due its involvement in the pathogenesis of disease processes
including inflammation, obesity, atherosclerosis, lymphedema, and
cancer [1–4]. Studies to elucidate the underlying mechanisms of
lymphatic development have identified vascular endothelial
growth factor-C (VEGF-C) as a key activator of lymphangiogen-
esis that functions via VEGF receptor-3 (VEGFR-3) on the surface
of lymphatic endothelial cells (LECs) [1,2,4]. However, a thorough
understanding of pathways that regulate lymphangiogenesis has
been limited, in part due to the lack of a rapid and physiologic in
vivo method to precisely measure lymphatic development.
Traditional wound healing models of pathologic lymphangio-
genesis rely on artificially-induced inflammation to stimulate
lymphatic growth and often lead to potential confounding
bystander effects from nearby pro-angiogenic or lymphangiogenic
inflammatory cells [5]. Moreover, this approach involves im-
munostaining of LECs for lymphangiogenesis quantification and
thus does not capture real-time changes in lymphatic growth.
Techniques attempting to reduce bystander effects, as well as
methods that employ in vivo imaging of lymphatic vessels, are
often lengthy, complicated, expensive, and permit only small
numbers of animals to be tested, thus limiting their use and
accessibility [6–8].
In recent years, the zebrafish (Danio rerio) has emerged as
a popular model to study vascular development. Zebrafish offer
many advantages, including rapid extrauterine growth, prolific
reproduction, and transparency during early stages of life allowing
for real-time in vivo imaging of development. Additionally, due to
conserved evolutionary pathways, numerous compounds specifi-
cally designed to be active in mammals cross-react with zebrafish,
occasionally by merely being added to the zebrafish aqueous
environment [9,10].
To date, lymphangiogenesis studies in zebrafish have focused
primarily on development of the thoracic duct [10,11]. However,
using lymphangiography, several additional lymphatic vessels in
the zebrafish trunk have been identified including a complex
network of blind-ended lymphatic capillaries by 18 days post-
fertilization (dpf) [11]. The appearance of this capillary network is
analogous to cells in tube formation assays used for in vitro
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quantification of lymphangiogenesis [12]; thus, we postulated that
a similar experimental approach, involving morphometric analysis
of in vivo lymphatic growth over time, could be applied to
lymphatic capillaries in early zebrafish development when
modifications to lymphatic growth may be most readily apparent.
In this study, the latter was accomplished by using a microangio-
graphic strategy to detect lymphatic capillaries in embryonic and
early larval zebrafish exposed to various modulators of lymphan-
giogenesis.
Methods
An expanded Methods section with associated references is
available online (File S1).
Ethics Statement
All animal experiments complied with the standards stated in
the Guide for the Care and Use of Laboratory Animals (Institute
of Laboratory Animal Resources, National Academy of Sciences,
Bethesda, MD) and were approved by the Mayo Clinic In-
stitutional Animal Care and Use Committee.
Animals
Zebrafish experiments utilized the Danio rerio transgenic line
Tg(fli1:EGFP)y1, expressing green fluorescent protein (GFP) in
vascular endothelium, described previously [13]. Zebrafish were
kept at 29uC in between experiments, unless otherwise indicated.
Cells and Reagents
For experiments quantifying lymphatic capillary development,
the following compounds were added directly to embryo water
(15 mM NaCl, 0.5 mM KCl, 1.0 mM MgSO4, 0.15 KH2PO4,
0.05 mM Na2HPO4, 1.0 mM CaCl2, 0.7 mM NaHCO3) contain-
ing approximately 10–20 zebrafish: recombinant human VEGF-C
(rhVEGF-C, R&D Systems, Minneapolis, MN), at a final concen-
tration of 200 pg/ml (enhanced capillary growth) or 100 pg/ml
(rescue of vegfc morpholino); rapamycin (Sigma-Aldrich, St. Louis,
MO) in dimethyl sulfoxide (DMSO) at a final concentration of
400 nM; human VEGF receptor-3 (hVEGFR-3) kinase inhibitor
(MAZ51; EMD Biosciences, San Diego, CA) in DMSO, at a final
concentration of 30 mM. Equivalent volumes of DMSO were
added to the embryo water of control zebrafish, corresponding to
the volumes of rapamycin (1 ml) and hVEGFR-3 inhibitor (4 ml)
used. All compounds were initially given on the day of fertilization
(day 0) and subsequently replaced every 24 hours in fresh embryo
water.
Lymphangiogenesis rescue experiments were conducted using
three cultured cell lines: human umbilical vein endothelial cells
(HUVECs; ATCC, Manassas, VA), B16 mouse melanoma cells
(ATCC) and human embryonic kidney 293 cells (ATCC) [14–16].
HUVECs were cultured in endothelial growth medium-2 (Lonza,
Walkersville, MD) supplemented with 2% fetal bovine serum
(FBS). B16 and 293 cells were cultured in Dulbecco’s Modified
Eagle Medium (Mediatech Inc, Manassas, VA) supplemented with
10% FBS.
Morpholino Injection
A morpholino antisense oligonucleotide used to inhibit trans-
lation of vegfc (59-TGAGCAGAGTCTCTTGAAAGTTCCC-39)
was a gift from Dr. Stephen Ekker. Solutions were prepared and
injected into zebrafish embryos on the day of fertilization (day 0)
up to the 4-cell stage, as described [17]. The morpholino dose
injected was 5 ng per embryo.
Xenotransplantation
Tricaine MS-222 (0.04 mg/mL, Sigma-Aldrich)-anesthetized 2-
dpf Tg(fli1:EGFP)y1 zebrafish, previously-injected with a vegfc
morpholino, were injected with 100–500 HUVECs, B16 or 293
cells labeled with CellTracker Orange (Invitrogen, Eugene, OR).
Prior to injection, cells were washed and resuspended in 0.9x PBS
supplemented with 0.3 U/ml heparin (APP Pharmaceuticals, LLC,
Schaumburg, IL) and 0.1 U/ml DNase (Roche Diagnostics,
Indianapolis, IN) to a final density of 26105/ml. Injections were
performed using a PL1-90 microinjector (Harvard Apparatus,
Holliston, MA) and borosilicate glass needles (1.5 mm outside
diameter, no filament; World Precision Instruments, Sarasota, FL)
made with a Flaming/Brown micropipette puller (Sutter Instru-
ments, Novato, CA), as previously-described [18]. Transplanted
zebrafish were kept overnight in embryo water at 37uC prior to
confocal imaging the next day (3 dpf).
Microangiography and Lymphangiography
Microangiography was performed as previously described [19];
however, 70 kilodalton (kDa) Texas Red-linked low molecular
weight dextran (Texas Red-LMD, Invitrogen) was used for these
studies. For early-phase microangiography, anesthetized zebrafish
were imaged by confocal microscopy at 15 minutes post-injection
to observe Texas Red-LMD within blood vessels. For late-phase
microangiography, zebrafish were imaged at 4 hours post-in-
jection, at which time Texas Red-LMD was visible within
lymphatic vessels. For whole zebrafish imaging, 2000 kDa
Fluorescein-linked high molecular weight dextran (Fluorescein-
HMD; Invitrogen) was co-injected with Texas Red-LMD to
enhance green fluorescence emitted by the GFP-expressing
zebrafish and to expose significant vascular leaks.
Traditional lymphangiography was performed as described
[11]. Imaging for early-phase and late-phase lymphangiography
was performed at 15 minutes and 4 hours post-injection, re-
spectively.
In Vivo Microscopy
At 2 dpf or 3 dpf, Tricaine-anesthetized Tg(fli1:EGFP)y1
zebrafish were imaged in embryo water using a Zeiss LSM780
inverted confocal microscope, equipped with argon and ultraviolet
lasers for multicolor analyses. Images were focused on the deep
lymphatic capillaries within the mid-trunk region.
Traditional two-channel modes were used to detect green and
red fluorescence in EGFP-expressing zebrafish injected with Texas
Red-LMD (488 nm filter for EGFP excitation, 561 nm filter for
Texas-Red excitation). The spectral mode of Zeiss LSM780 was
used to detect three fluorophores in EGFP-expressing zebrafish
injected with both Texas Red-LMD and CellTracker Orange-
labeled cells (594 nm filter for excitation), as previously described
[20,21]. CellTracker Orange-labeled cells were pseudo-colored
blue to distinguish them from vessels containing Texas Red-LMD.
Quantitative Method to Assess Lymphangiogenesis
For each Tg(fli1:EGFP)y1 zebrafish analyzed, confocal images of
the mid-trunk region spanning approximately 5–7 somitic
interspaces (defined as the region between two consecutive somitic
boundary clefts filled with Texas Red-LMD) were acquired for
quantification. The area contained within four consecutive somitic
interspaces (starting with the most anterior interspace) was used for
lymphatic capillary quantification. Morphometric analyses were
performed using MetaMorph microscopy automation and image
analysis software (Molecular Devices, LLC, Sunnyvale, CA). The
average total capillary length for each treatment group imaged
In Vivo Quantification of Lymphangiogenesis
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over three or more independent experiments was subsequently
calculated. The results were expressed as the mean lymphatic
capillary length (mM) per unit area.
Immunoblotting
Cell lysates were obtained from HUVECs, B16, and 293 cells
using cell lysis buffer in the presence of protease inhibitors (Roche).
Conditioned media was also collected. After centrifugation to
remove cell debris, samples were denatured and then subjected to
sodium dodecyl sulphate polyacrylamide gel electrophoresis under
reducing conditions, followed by transfer onto a polyvinylidene
fluoride membrane (Biorad Laboratories, Hercules, CA). After
blocking with Tris-buffered saline-0.05%Tween containing 5%
milk, blots were incubated with 1:100 anti-VEGF-C antibody (sc-
1881; Santa Cruz Biotechnology, Santa Cruz, CA) or 1:2000 anti-
a-Tubulin (T6199; Sigma-Aldrich), followed by incubation with
appropriate secondary antibodies (Santa Cruz) and ECL chemi-
luminescence detection system (Fisher Pierce, Rockford, IL) as per
the manufacturer’s instructions.
Bright-field and Fluorescence Microscopy
Bright-field, green, and red fluorescence images (5x) of un-
treated Tricaine-anesthetized Tg(fli1:EGFP)y1 zebrafish as well as
those injected with a vegfc morpholino or exposed to hVEGFR-3
inhibitor or rapamycin were taken in embryo water using a Zeiss
Axio Observer.A1 inverted fluorescent microscope equipped with
a Sony HDR-HC9 high-definition video camera.
Statistical Analysis
Statistics were performed using GraphPad Prism 4 software.
Results are expressed as mean 6 SEM. Differences between
groups were analyzed for statistical significance using an unpaired
two-tailed Student t test.
Results
Detection of Deep Trunk Lymphatic Capillaries Early in
Zebrafish Development
The presence of lymphatic capillaries in 3-dpf (larval)
Tg(fli1:EGFP)y1 zebrafish were confirmed by employing a lymph-
angiography technique previously used to identify trunk lympha-
tics in older zebrafish [11], in which fluorescently-linked dextran
was injected subcutaneously into the posterior tail (Figure 1A).
However, in this study, Texas Red-LMD was utilized rather than
fluorescently-linked HMD as it was presumed that nascent
lymphatic vessels at 3 dpf would more readily absorb LMD.
Fifteen minutes post-injection (early-phase), confocal imaging of
the mid-trunk region revealed chevron-shaped extravascular
collections of Texas-Red LMD in somite boundary clefts [22],
distinguished from intersegmental blood vessels (ISVs) expressing
GFP in vascular endothelium (Figure 1B). Additionally, several
deep lymphatic vessels were visible and appeared to be partially
filled with Texas Red-LMD. By 4 hours post-injection (late-phase),
significantly more of the deep lymphatics, but no ISVs, contained
Texas Red-LMD and were seen to comprise an intricate array of
blind-ended capillaries (Figure 1C), corresponding to the lym-
phatic network previously observed in 18-dpf zebrafish [11].
Unexpectedly, these initial experiments revealed a potential
drawback of lymphangiography as a technique for lymphatic
capillary visualization; namely, the frequent appearance of excess
Texas Red-LMD diffusing from subcutaneous injection sites as
blotches that obscure lymphatic capillaries (Figure 1D, E). Thus,
an alternative imaging method that would unambiguously reveal
lymphatic capillaries for quantification was sought. It was
discovered that late-phase microangiography with Texas Red-
LMD was one such approach.
Microangiography was performed by intracardiac injection of
Texas-Red LMD into 3-dpf Tg(fli1:EGFP)y1 zebrafish (Figure 2A).
Fifteen minutes post-injection (early-phase), Texas Red-LMD was
contained almost exclusively within ISVs and not in any putative
lymphatic capillaries (Figure 2B), further specifying the lymphatic
origin of the latter. However, due to the small size of Texas Red-
LMD and considerable permeability of developing blood vessels in
3-dpf zebrafish, most Texas Red-LMD had leaked from the GFP-
expressing vasculature by 4 hours post-injection (late-phase) and
either collected at somite boundaries or was absorbed by
lymphatic capillaries, essentially simulating a late-phase lymphan-
giogram (Figure 2C). Thus, late-phase microangiography, a tech-
nique that requires approximately the same amount of time as
lymphangiography to clearly visualize lymphatic capillaries but
does so more reliably with the added advantage of illuminating
blood vessels, was employed for all subsequent experiments.
Zebrafish Lymphatic Capillary Development is Regulated
by VEGF-C
To determine if zebrafish lymphatic capillary growth is
mediated by known activators of lymphangiogenesis, zebrafish
embryos were injected with a morpholino, previously shown to
specifically inhibit the vegfc ortholog in zebrafish [10,11].
Knockdown of vegfc expression induced a significant decrease in
lymphatic capillary growth compared to untreated zebrafish at 3
dpf (Figure 3A, B), while only causing other mild phenotypic
changes such as trace edema and occasional small blood vessel
defects (Figure S1), indicating that vegfc is critical for lymphatic
capillary development. Specificity of vegfc knockdown was
confirmed by a rescue experiment in which exogenous rhVEGF-
C (a prospective treatment for human lymphedema [23]) restored
lymphatic capillary growth by 3 dpf when added to the aqueous
environment of vegfc morphant zebrafish (Figure 3A, B).
The effect of rhVEGF-C on lymphatic capillary development in
non-morphant zebrafish was also assessed. Similar to a previous
study examining the effect of rhVEGF on vascular development in
embryonic zebrafish [9], rhVEGF-C was added daily to the
zebrafish aqueous environment, starting at approximately 1 hour
post-fertilization (hpf). Lymphatic capillary growth was sub-
sequently quantified by morphometric analyses of late-phase
microangiograms at 2-dpf (late embryonic stage), since, at baseline,
2-dpf zebrafish demonstrate substantially fewer lymphatic capil-
laries than 3-dpf zebrafish (Figure 4A, B). Consequently, 2-dpf
zebrafish exposed to rhVEGF-C exhibited a significant increase in
lymphatic capillary growth compared to untreated 2-dpf zebrafish
(Figure 4A, B), but no detectable increase in lymphatic capillary
growth above baseline at 3-dpf (Figure 3A). The lack of sustained
activation of lymphangiogenesis by rhVEGF-C is uncertain but
could be related to decreased permeability of the zebrafish
integument by the time of hatching (approximately 50 hpf),
inhibiting further rhVEGF-C absorption, or perhaps an intrinsic
zebrafish homeostatic mechanism, preventing potentially harmful
excessive lymphatic growth at 3 dpf.
Suppression of Zebrafish Lymphatic Capillary
Development by Small Molecules
Zebrafish lymphatic capillary development in the presence of
chemical inhibitors of lymphatic growth was assessed. The
hVEGFR-3 inhibitor (MAZ51) was added to the zebrafish
aqueous environment at a dose (30 mM) reported to specifically
inhibit lymphangiogenesis in human cells in vitro and Xenopus
In Vivo Quantification of Lymphangiogenesis
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tadpoles in vivo [24,25] and resulted in significantly fewer
lymphatic capillaries than untreated zebrafish by 3 dpf
(Figure 5A, B) but virtually no other detectable phenotypic
changes (Figure S1). Zebrafish exposed to rapamycin, an in vivo
inhibitor of lymphangiogenesis in both humans and zebrafish
[10,26–30], at a dose (400 nM) reported to suppress zebrafish
thoracic duct development [10], exhibited a particularly striking
inhibition of lymphatic capillary growth by 3 dpf (Figure 5C, D). It
is unclear if this inhibition was related to a direct or indirect effect
on lymphatic capillary development, as zebrafish exposed to
rapamycin were markedly smaller than untreated zebrafish at 3
dpf; nonetheless, the other phenotypic features of rapamycin-
treated zebrafish suggested successful targeting of lymphangiogen-
esis pathways, including large pericardial and yolk sac edema as
well as increased vascular permeability (Figure S1), which were
not improved by the addition of rhVEGF-C (data not shown).
Zebrafish Lymphatic Capillary Development is Stimulated
by Human Endothelial and Mouse Melanoma Cells
Lymphatic capillary development in zebrafish transplanted with
human endothelial cells, known to secrete numerous VEGF
growth factors [31], and murine cancer cells, which may facilitate
metastasis by activating lymphatic growth [1], was assessed.
Xenotransplantation is an important technique to study cell
function in zebrafish, made possible by the fact that the latter do
not have an effective immune response during early development
and thus do not undergo transplant rejection [18]. The cells are
typically given by intracardiac injection beyond 48 hpf to ensure
adequate development of the cardiovascular system. Thus, to
improve the likelihood of detecting an increase in lymphatic
capillary growth, a vegfc morpholino was injected prior to
transplantation. At 2-dpf, vegfc morphants were transplanted with
human endothelial cells (HUVECs), as well as mouse melanoma
cells (B16) and human embryonic kidney (293) cells as controls, via
intracardiac injection. After overnight incubation of transplanted
zebrafish at 37uC, all three injected cell types appeared to have
increased in number relative to the original amount of cells
injected and had taken up residence in the major blood vessels, but
human endothelial and kidney cells also appeared extravascularly
in the deep tissues bordering lymphatic capillaries (Figure 6A–C).
Notably, morphant zebrafish transplanted with human endothelial
and mouse melanoma cells, but not human kidney cells, had
significantly more lymphatic capillary growth than untransplanted
morphants (Figure 6D); however, the level of rescue did not
correlate directly with the level of activated VEGF-C expression in
vitro (Figure 6E).
Discussion
Lymphangiogenesis is involved in the pathogenesis of numerous
disease processes, including lymphedema, inflammation, obesity,
atherosclerosis, and cancer. However, our current understanding
of the mechanisms underlying lymphatic development is limited
because of inadequate animal model systems to precisely measure
lymphatic growth, impeding both the advancement of basic
scientific research as well as the discovery of new drug targets. In
the present study, this technical shortcoming is addressed through
the development of an in vivo method to quantify lymphangiogen-
esis in zebrafish.
Figure 1. Lymphangiography reveals lymphatic capillaries in early zebrafish development. A, Subcutaneous injection technique
employed for lymphangiography. The narrow red triangle represents the needle used to inject Texas Red-LMD into the zebrafish posterior tail. The
black box demarcates the approximate region of the trunk imaged. B and C, Ideal lymphangiogram of 3-dpf Tg(fli1:EGFP)y1 zebrafish (green blood
vessels). B, At 15 minutes post-injection (early-phase), green ISVs (large white arrows) are distinguished from extravascular collections of Texas Red-
LMD at somitic boundaries (yellow arrowheads) and small red lymphatic vessels (small white arrows) deep to and within the somitic interspaces. C, At
4 hours post-injection (late-phase), Texas Red-LMD is still not present within ISVs (large white arrows); however, more of the small lymphatics contain
Texas Red-LMD and comprise an intricate array of capillaries (small white arrows). D and E, Typical lymphangiogram at 15 minutes and 4 hours post-
injection, in which images are partially-obscured by blotches of Texas Red-LMD (green arrows) that diffused from the original subcutaneous site.
Scale bars, 50 mm.
doi:10.1371/journal.pone.0045240.g001
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Previous lymphatic studies in zebrafish have concentrated
primarily on development of the thoracic duct, which provides
a qualitative measure of lymphangiogenesis but is not suitable to
quantify changes in lymphatic growth [10,11]. In this study, trunk
lymphatic capillaries, resembling cells in tubulogenesis assays
amenable to morphometric analyses, were assessed. Using
fluorescently-linked LMD and late-phase microangiography,
a complementary imaging approach to lymphangiography,
zebrafish trunk lymphatic capillaries were detected in embryonic
and early larval stages. This is the first report in which trunk
lymphatic capillaries were visualized as early as 2 dpf. Prior
investigations employing lymphangiography failed to detect
lymphatic capillaries until several weeks post-fertilization, perhaps
related to the use of fluorescently-linked HMD that may not be
absorbed by developing lymphatic capillaries [11].
In this study, detection of early lymphatic capillary growth,
a dynamic but predictable physiologic process, allowed for the
quantification of lymphatic development in zebrafish. Human
modulators of lymphangiogenesis, including an activator
(rhVEGF-C) and multiple small molecule inhibitors (hVEGFR-3
inhibitor and rapamycin), reproducibly and specifically altered
lymphatic capillary development, and human endothelial and
mouse melanoma cells transplanted into zebrafish stimulated
a measurable increase in lymphatic capillary growth after
suppression with a vegfc morpholino. These findings underscore
several key advantages of using the zebrafish model to measure
lymphangiogenesis.
One advantage is the ability to detect real-time changes in
lymphatic growth in large numbers of zebrafish after the addition
of protein or chemical lymphangiogenesis modulators to the
aqueous environment. The latter is the simplest route of delivery
used in any in vivo model of lymphangiogenesis and leads to
detectable increases or decreases in lymphatic growth within a few
days. In contrast, many current methods for quantifying patho-
logic lymphangiogenesis permit only small numbers of animals to
be tested, because they require complex surgical techniques such
as suturing or pellet implantation of the mouse cornea in order to
observe a change in lymphatic development that frequently does
not occur for 1 or 2 weeks [5,6,32]. Moreover, these assays are
useful only to study activation and not inhibition of lymphangio-
genesis, since they rely on tissues that are initially devoid of
lymphatics, and also provide instantaneous rather than real-time
images of lymphatic growth, since immunostaining of selected
tissue sections is required.
Another advantage of the zebrafish model is the ability to assess
the effects of cells derived from multiple species on lymphangio-
genesis in vivo, since zebrafish lack a functional immune system
during embryonic and early larval stages. To our knowledge, this
is the first report of xenotransplantation as a method to evaluate
cellular roles in lymphatic development. Many cell types are
believed to influence lymphangiogenesis, ranging from vascular
endothelial cells primarily during embryonic development and
inflammation, to cancer cells undergoing metastasis [1,2]. Pre-
viously, human endothelial cells were presumed to have a stimu-
latory effect on lymphangiogenesis based solely on their ability to
express activated VEGF-C and stimulate LECs in vitro [33], while
Figure 2. Late-phase microangiography clearly demonstrates
lymphatic capillaries in early zebrafish development. A, In-
tracardiac injection technique employed for microangiography. The
narrow red triangle represents the needle used to inject Texas Red-LMD
into the zebrafish heart. The black box demarcates the approximate
region of the trunk imaged. B and C, Microangiogram of 3-dpf
Tg(fli1:EGFP)y1 zebrafish. B, At 15 minutes post-injection (early-phase),
Texas Red-LMD is primarily within ISVs (large white arrows), and
lymphatic capillaries contain no Texas Red-LMD. C, By 4 hours post-
injection (late-phase), most Texas Red-LMD has leaked from the blood
vessels and collected at somitic boundaries (yellow arrowheads) or
within deep lymphatic capillaries (small white arrows). Scale bar, 50 mm.
doi:10.1371/journal.pone.0045240.g002
Figure 3. Quantification of lymphatic capillary development after knockdown with a vegfc morpholino. Red fluorescent images from
late-phase microangiograms of Tg(fli1:EGFP)y1 zebrafish are shown, highlighting Texas Red-LMD uptake within lymphatic capillaries. Results of
quantitative morphometric analyses are displayed in bar graphs. A and B, Zebrafish injected with a vegfc morpholino (MO) have significant inhibition
of lymphatic capillary growth at 3 dpf (n = 32) compared to untreated zebrafish (n = 32) or those exposed to rhVEGF-C (n = 14), which is mitigated by
the addition of rhVEGF-C (100 pg/ml) to the aqueous environment (n = 15). *P,0.0001, **P,0.0001. Scale bars, 50 mm.
doi:10.1371/journal.pone.0045240.g003
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mouse melanoma cells were considered to be only slightly
lymphangiogenic based on a lack of activated VEGF-C production
in vitro and minimal stimulation of lymphangiogenesis in vivo in
murine studies of melanoma [34]. In this report, both cell types
were capable of rescuing lymphatic growth in zebrafish following
knockdown of vegfc, a particularly impressive finding given the fact
that these morphants were less likely to thrive and develop under
the extremely warm conditions used to maintain viability of
transplanted cells. Thus, human endothelial cells, as well as mouse
melanoma cells under the correct physiologic conditions, are
capable of stimulating lymphatic development in vivo. Interest-
ingly, mouse melanoma cells stimulated lymphatic growth to
a greater degree than human endothelial cells in zebrafish, but the
level of stimulation did not correlate directly with in vitro
production of biologically-active VEGF-C, since only cultured
human endothelial cells expressed the fully processed form of the
protein. Mouse melanoma cells may therefore promote lymphan-
giogenesis through an alternative pathway to the VEGF-C/
VEGFR-3 axis. Additional studies combining morpholino gene
silencing with xenotransplantation may help elucidate the
mechanisms by which human endothelial cells and mouse
melanoma cells (as well as other endothelial and cancer cell types)
stimulate lymphangiogenesis in zebrafish.
Despite many advantages, the method presented in this study
does have distinct requirements. A moderate amount of technical
expertise is required to perform injections in embryonic and larval
zebrafish during microangiography, lymphangiography, and
xenotransplantation experiments. Additionally, in vivo imaging is
a rate-limiting step and requires the appropriate confocal
microscopy equipment and software to visualize lymphatic
capillaries early in development or perform 3-color spectral
analyses after cell transplantation. The assay is temporally
constrained by specific time-points at which injections, treatments,
and imaging must occur and potentially confounded by variability
in lymphatic capillary growth patterns occurring among different
clutches of zebrafish embryos; although, the latter should be
Figure 4. Quantification of lymphatic capillary development after stimulation with rhVEGF-C. Red fluorescent images from late-phase
microangiograms of Tg(fli1:EGFP)y1 zebrafish are shown, highlighting Texas Red-LMD uptake within lymphatic capillaries. Results of quantitative
morphometric analyses are displayed in bar graphs. A and B, At 2 dpf, fewer lymphatic capillaries are present in untreated zebrafish (n = 18),
compared to 3-dpf untreated zebrafish (n = 32), but they increase significantly with the addition of rhVEGF-C to the zebrafish aqueous environment
(n = 18). *P,0.0001, **P,0.0001. Scale bars, 50 mm.
doi:10.1371/journal.pone.0045240.g004
Figure 5. Quantification of lymphatic capillary development after inhibition with small molecules. Red fluorescent images from late-
phase microangiograms of Tg(fli1:EGFP)y1 zebrafish are shown, highlighting Texas Red-LMD uptake within lymphatic capillaries. Results of
quantitative morphometric analyses are displayed in bar graphs. A and B, Addition of hVEGFR-3 inhibitor in DMSO (n= 30) or rapamycin in DMSO
(n = 18) to the aqueous environment significantly reduced lymphatic capillary development at 3 dpf, compared to zebrafish exposed to DMSO alone
(n = 21 and 15, respectively). *P,0.0001, **P,0.0001. Scale bars, 50 mm.
doi:10.1371/journal.pone.0045240.g005
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compensated by the ability to test large numbers of animals with
this assay.
In summary, this is the first report of an in vivo method to
quantify lymphangiogenesis in zebrafish. Contrary to most
currently available models, the zebrafish model presented here is
physiologic and permits large numbers of animals to be tested.
Additionally, it is simple in design, provides rapid results, involves
real-time imaging, and can be used to test the effects of numerous
cell types on lymphatic growth. The ability to rapidly measure
changes in lymphangiogenesis under physiologic conditions has
broad implications. It opens the door to phenotypic characteriza-
tion studies of lymphatic development in zebrafish, in conjunction
with the large array of established mutant and transgenic lines,
and will enable screening of additional lymphangiogenesis
modulators. Moreover, it has the potential to help clarify
mechanisms by which numerous cells alter lymphatic growth as
well as elucidate pathways of lymphangiogenesis, the results of
which will advance our understanding of disease.
Supporting Information
Figure S1 Zebrafish phenotype after vegfc morpholino
injection or exposure to rapamycin or VEGFR-3 in-
hibitor. A–E, Representative bright field and green or red
fluorescence microscopy images of whole Tg(fli1:EGFP)y1 zebrafish
after microangiography with Texas Red-LMD and Fluorescein-
HMD*, including untreated 2-dpf and 3-dpf zebrafish, or 3-dpf
zebrafish subjected to (C) vegfc MO (5 ng), (D) hVEGFR-3
inhibitor (30 mM) or (E) rapamycin (400 ng/ml). Note, all
lymphangiogenesis inhibitors (C–E) led to pericardial edema
(black arrows), but it was most prominent in zebrafish exposed to
rapamycin. The latter also had significant yolk sac edema (black
arrowhead), and an apparent collection of fluorescently-linked
dextran in the posterior trunk (white arrows), suggesting a blood
vessel leak versus lymphedema. *Fluorescein-HMD was co-
injected with Texas Red-LMD during microangiography to
enhance the green fluorescent signal emitted by the GFP-
expressing zebrafish, as well as expose significant vascular leaks.
(TIF)
File S1 Detailed methods.
(DOC)
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Figure 6. Quantification of lymphatic capillary development after xenotransplantation. Green fluorescent images (fli1:EGFP) reveal blood
vessels, red fluorescent images (Texas Red-LMD) reveal lymphatic capillaries, and blue fluorescent images (CellTracker) reveal transplanted cells in 3-
dpf Tg(fli1:EGFP)y1 zebrafish. Results of quantitative morphometric analyses are displayed in bar graphs. A–D, At 3 dpf (n = 32), the inhibitory effect of
the vegfc morpholino MO (n= 32) was rescued by transplantation of HUVECs (n = 18) and B16 cells (n = 20), but not 293 cells (n = 25). *P = 0.0005,
**P,0.0001. Scale bars, 50 mM. All cell types (blue) were detected in major blood vessels, including the dorsal aorta (white arrowheads). HUVECs and
293 cells were also seen extravascularly, bordering lymphatic capillaries (white arrows). Note: fewer ISVs (green) in images of B16- or 293-injected
morphants relates to the particular focal plane imaged, since alternative focal planes revealed approximately normal numbers of ISVs in these and
other similarly-treated zebrafish (data not shown). E, Immunoblot to detect human VEGF-C in cultured HUVEC, B16, and 293 cells. The active,
proteolytically-processed form of VEGF-C (21 kilodaltons, kDa) was only detected at appreciable levels in HUVEC lysate. B16 and 293 cell lysates
contained VEGF-C in a dimerized precursor form (80 kDa). No VEGF-C was detected in conditioned media from any of the cells (data not shown). An
antibody against a-tubulin was used as a loading control.
doi:10.1371/journal.pone.0045240.g006
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